Identification of pathogenic gene mutations in LMNA and MYBPC3 that alter RNA splicing

Kaoru Ito, Parth N. Patel, Joshua M. Gorham, Barbara McDonough, Steven R. DePalma, Emily E. Adler, Lien Lam, Calum A. MacRae, Syed M. Mohiuddin, Diane Fatkin, Christine E. Seidman, J. G. Seidman

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Genetic variants that cause haploinsufficiency account for many autosomal dominant (AD) disorders. Gene-based diagnosis classifies variants that alter canonical splice signals as pathogenic, but due to imperfect understanding of RNA splice signals other variants that may create or eliminate splice sites are often clinically classified as variants of unknown significance (VUS). To improve recognition of pathogenic splice-altering variants in AD disorders, we used computational tools to prioritize VUS and developed a cell-based minigene splicing assay to confirm aberrant splicing. Using this two-step procedure we evaluated all rare variants in two AD cardiomyopathy genes, lamin A/C (LMNA) and myosin binding protein C (MYBPC3). We demonstrate that 13 LMNA and 35 MYBPC3 variants identified in cardiomyopathy patients alter RNA splicing, representing a 50% increase in the numbers of established damaging splice variants in these genes. Over half of these variants are annotated as VUS by clinical diagnostic laboratories. Familial analyses of one variant, a synonymous LMNA VUS, demonstrated segregation with cardiomyopathy affection status and altered cardiac LMNA splicing. Application of this strategy should improve diagnostic accuracy and variant classification in other haploinsufficient AD disorders.

Original languageEnglish (US)
Pages (from-to)7689-7694
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume114
Issue number29
DOIs
StatePublished - Jul 18 2017

Fingerprint

Lamin Type A
RNA Splicing
Cardiomyopathies
Mutation
Genes
Haploinsufficiency
Dominant Genes
RNA

All Science Journal Classification (ASJC) codes

  • General

Cite this

Identification of pathogenic gene mutations in LMNA and MYBPC3 that alter RNA splicing. / Ito, Kaoru; Patel, Parth N.; Gorham, Joshua M.; McDonough, Barbara; DePalma, Steven R.; Adler, Emily E.; Lam, Lien; MacRae, Calum A.; Mohiuddin, Syed M.; Fatkin, Diane; Seidman, Christine E.; Seidman, J. G.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 114, No. 29, 18.07.2017, p. 7689-7694.

Research output: Contribution to journalArticle

Ito, K, Patel, PN, Gorham, JM, McDonough, B, DePalma, SR, Adler, EE, Lam, L, MacRae, CA, Mohiuddin, SM, Fatkin, D, Seidman, CE & Seidman, JG 2017, 'Identification of pathogenic gene mutations in LMNA and MYBPC3 that alter RNA splicing', Proceedings of the National Academy of Sciences of the United States of America, vol. 114, no. 29, pp. 7689-7694. https://doi.org/10.1073/pnas.1707741114
Ito, Kaoru ; Patel, Parth N. ; Gorham, Joshua M. ; McDonough, Barbara ; DePalma, Steven R. ; Adler, Emily E. ; Lam, Lien ; MacRae, Calum A. ; Mohiuddin, Syed M. ; Fatkin, Diane ; Seidman, Christine E. ; Seidman, J. G. / Identification of pathogenic gene mutations in LMNA and MYBPC3 that alter RNA splicing. In: Proceedings of the National Academy of Sciences of the United States of America. 2017 ; Vol. 114, No. 29. pp. 7689-7694.
@article{c87e689d82674500930b34c72ec932f3,
title = "Identification of pathogenic gene mutations in LMNA and MYBPC3 that alter RNA splicing",
abstract = "Genetic variants that cause haploinsufficiency account for many autosomal dominant (AD) disorders. Gene-based diagnosis classifies variants that alter canonical splice signals as pathogenic, but due to imperfect understanding of RNA splice signals other variants that may create or eliminate splice sites are often clinically classified as variants of unknown significance (VUS). To improve recognition of pathogenic splice-altering variants in AD disorders, we used computational tools to prioritize VUS and developed a cell-based minigene splicing assay to confirm aberrant splicing. Using this two-step procedure we evaluated all rare variants in two AD cardiomyopathy genes, lamin A/C (LMNA) and myosin binding protein C (MYBPC3). We demonstrate that 13 LMNA and 35 MYBPC3 variants identified in cardiomyopathy patients alter RNA splicing, representing a 50{\%} increase in the numbers of established damaging splice variants in these genes. Over half of these variants are annotated as VUS by clinical diagnostic laboratories. Familial analyses of one variant, a synonymous LMNA VUS, demonstrated segregation with cardiomyopathy affection status and altered cardiac LMNA splicing. Application of this strategy should improve diagnostic accuracy and variant classification in other haploinsufficient AD disorders.",
author = "Kaoru Ito and Patel, {Parth N.} and Gorham, {Joshua M.} and Barbara McDonough and DePalma, {Steven R.} and Adler, {Emily E.} and Lien Lam and MacRae, {Calum A.} and Mohiuddin, {Syed M.} and Diane Fatkin and Seidman, {Christine E.} and Seidman, {J. G.}",
year = "2017",
month = "7",
day = "18",
doi = "10.1073/pnas.1707741114",
language = "English (US)",
volume = "114",
pages = "7689--7694",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "29",

}

TY - JOUR

T1 - Identification of pathogenic gene mutations in LMNA and MYBPC3 that alter RNA splicing

AU - Ito, Kaoru

AU - Patel, Parth N.

AU - Gorham, Joshua M.

AU - McDonough, Barbara

AU - DePalma, Steven R.

AU - Adler, Emily E.

AU - Lam, Lien

AU - MacRae, Calum A.

AU - Mohiuddin, Syed M.

AU - Fatkin, Diane

AU - Seidman, Christine E.

AU - Seidman, J. G.

PY - 2017/7/18

Y1 - 2017/7/18

N2 - Genetic variants that cause haploinsufficiency account for many autosomal dominant (AD) disorders. Gene-based diagnosis classifies variants that alter canonical splice signals as pathogenic, but due to imperfect understanding of RNA splice signals other variants that may create or eliminate splice sites are often clinically classified as variants of unknown significance (VUS). To improve recognition of pathogenic splice-altering variants in AD disorders, we used computational tools to prioritize VUS and developed a cell-based minigene splicing assay to confirm aberrant splicing. Using this two-step procedure we evaluated all rare variants in two AD cardiomyopathy genes, lamin A/C (LMNA) and myosin binding protein C (MYBPC3). We demonstrate that 13 LMNA and 35 MYBPC3 variants identified in cardiomyopathy patients alter RNA splicing, representing a 50% increase in the numbers of established damaging splice variants in these genes. Over half of these variants are annotated as VUS by clinical diagnostic laboratories. Familial analyses of one variant, a synonymous LMNA VUS, demonstrated segregation with cardiomyopathy affection status and altered cardiac LMNA splicing. Application of this strategy should improve diagnostic accuracy and variant classification in other haploinsufficient AD disorders.

AB - Genetic variants that cause haploinsufficiency account for many autosomal dominant (AD) disorders. Gene-based diagnosis classifies variants that alter canonical splice signals as pathogenic, but due to imperfect understanding of RNA splice signals other variants that may create or eliminate splice sites are often clinically classified as variants of unknown significance (VUS). To improve recognition of pathogenic splice-altering variants in AD disorders, we used computational tools to prioritize VUS and developed a cell-based minigene splicing assay to confirm aberrant splicing. Using this two-step procedure we evaluated all rare variants in two AD cardiomyopathy genes, lamin A/C (LMNA) and myosin binding protein C (MYBPC3). We demonstrate that 13 LMNA and 35 MYBPC3 variants identified in cardiomyopathy patients alter RNA splicing, representing a 50% increase in the numbers of established damaging splice variants in these genes. Over half of these variants are annotated as VUS by clinical diagnostic laboratories. Familial analyses of one variant, a synonymous LMNA VUS, demonstrated segregation with cardiomyopathy affection status and altered cardiac LMNA splicing. Application of this strategy should improve diagnostic accuracy and variant classification in other haploinsufficient AD disorders.

UR - http://www.scopus.com/inward/record.url?scp=85024406213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024406213&partnerID=8YFLogxK

U2 - 10.1073/pnas.1707741114

DO - 10.1073/pnas.1707741114

M3 - Article

VL - 114

SP - 7689

EP - 7694

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 29

ER -